论文部分内容阅读
目的探讨分析调强放疗联合替吉奥胶囊治疗不能切除胆管癌的临床效果。方法回顾性分析2012年12月—2015年2月本院收治的60例不能切除的胆管癌患者的临床资料,随机分为对照组和治疗组各30例。对照组采用调强放疗,治疗组在对照组的基础上联合替吉奥胶囊治疗。记录并比较两组治疗效果、生存情况及不良反应发生情况。计量资料采用t检验,计数资料采用χ2检验,等级资料采用秩和检验,P<0.05为差异有统计学意义。结果治疗组总有效率为86.67%,高于对照组的60.00%,差异有统计学意义(P<0.05)。治疗组1年生存率、1年局部控制率以及中位生存时间分别为83.33%、66.67%、(13.36±0.95)个月,均高于对照组的53.33%、36.67%、(10.28±0.47)个月,差异均有统计学意义(均P<0.05)。结论调强放疗联合替吉奥胶囊治疗不能切除的胆管癌临床效果显著,具有临床推广价值。
Objective To investigate the clinical effect of combined intensity-modulated radiotherapy and teglitazone capsule in the treatment of unresectable cholangiocarcinoma. Methods The clinical data of 60 unresectable cholangiocarcinoma patients who were admitted to our hospital from December 2012 to February 2015 were retrospectively analyzed and randomly divided into control group and treatment group of 30 cases. In the control group, IMRT was used, and the treatment group was treated on the basis of the control group for the treatment of GIO capsules. Record and compare the two groups of treatment effect, survival and adverse reactions. Measurement data using t test, count data using χ2 test, grade data using rank sum test, P <0.05 for the difference was statistically significant. Results The total effective rate of the treatment group was 86.67%, which was higher than that of the control group (60.00%), the difference was statistically significant (P <0.05). The 1-year survival rate, 1-year local control rate and median survival time in the treatment group were 83.33%, 66.67% and 13.36 ± 0.95 months, respectively, which were all higher than those in the control group (53.33%, 36.67%, 10.28 ± 0.47) Months, the differences were statistically significant (all P <0.05). Conclusion Intensive radiotherapy and tegaserod capsules in treatment of unresectable cholangiocarcinoma have significant clinical effect and clinical value.